Core Insights - The primary market is set for an active period with five IPOs scheduled between November 11 and 14, aiming to raise over Rs 10,000 crore, indicating strong fundraising activity [5][6] Mainboard IPOs - **PhysicsWallah**: An edtech company planning to launch a Rs 3,480 crore IPO on November 11, with shares priced between Rs 103–109. The funds will be used for technology infrastructure, new learning centers, and acquisitions [5][6] - **Tenneco Clean Air India**: A subsidiary of Tenneco Inc., this company is set to offer a Rs 3,600 crore IPO from November 12 to 14, entirely through an offer for sale. The shares are priced between Rs 378–397, with a grey market premium of about 24% [6] - **Emmvee Photovoltaic Power**: A solar panel manufacturer aiming to raise Rs 2,900 crore with bids accepted from November 11 to 13, priced in the Rs 206–217 band [3][6] SME IPOs - **Mahamaya Lifesciences**: A specialty pharmaceutical firm opening its issue on November 11, aiming to raise Rs 70.44 crore at a price band of Rs 108–114 [4][6] - **Workmates Core2Cloud Solution**: Specializing in cloud services and cybersecurity, this company plans to raise Rs 69.84 crore with shares priced between Rs 200–204, also opening on November 11 [4][6] Market Dynamics - The upcoming IPOs span various sectors including education, clean energy, automotive technology, and pharmaceuticals, reflecting a diverse investment landscape [4][5][6]

Company Performance - Zoetis reported an outstanding performance in 2024, achieving the second highest growth rate in its public company history [4] - The major franchises in companion animal products led the growth with double-digit increases [4] - Livestock products also showed consistent growth, increasing by 5% and 6% over the last two years [4] Industry Insights - The industry is characterized as incredibly resilient and still young, presenting substantial opportunities for expansion [4] - Zoetis holds a leadership position in existing markets such as dermatology and parasiticides, particularly with the Simparica franchise [4] - There is significant potential for growth in new markets, particularly in osteoarthritis (OA) pain management, where the company is just beginning to explore opportunities [4]